Calingaert B - Search Results

1

Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Vine MF, et al. Among authors: calingaert b. Gynecol Oncol. 2001 Dec;83(3):466-71. doi: 10.1006/gyno.2001.6411. Gynecol Oncol. 2001. PMID: 11733956

2

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Vine MF, et al. Among authors: calingaert b. Gynecol Oncol. 2003 Jul;90(1):75-82. doi: 10.1016/s0090-8258(03)00175-6. Gynecol Oncol. 2003. PMID: 12821345

3

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.

Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. Among authors: calingaert b. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782

4

Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.

Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Spillman MA, et al. Among authors: calingaert b. Gynecol Oncol. 2005 May;97(2):543-9. doi: 10.1016/j.ygyno.2005.01.025. Gynecol Oncol. 2005. PMID: 15863158

5

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Schildkraut JM, et al. Among authors: calingaert b. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8. doi: 10.1093/jnci/94.1.32. J Natl Cancer Inst. 2002. PMID: 11773280

6

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Moorman PG, et al. Among authors: calingaert b. Cancer Causes Control. 2002 Nov;13(9):807-11. doi: 10.1023/a:1020678100977. Cancer Causes Control. 2002. PMID: 12462545

7

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Among authors: calingaert b. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

8

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Among authors: calingaert b. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

9

Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.

Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Wenham RM, et al. Among authors: calingaert b. Clin Cancer Res. 2003 Oct 1;9(12):4396-403. Clin Cancer Res. 2003. PMID: 14555511

10

Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.

Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Berchuck A, et al. Among authors: calingaert b. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters